Influencia de los niveles de ácido úrico sobre el riesgo de mortalidad cardiovascular a largo plazo en pacientes con diabetes de tipo 2

Haffner, 1998, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N Engl J Med, 339, 229, 10.1056/NEJM199807233390404 Sattar, 2013, Revisiting the links between glycaemia, diabetes and cardiovascular disease, Diabetologia, 56, 686, 10.1007/s00125-012-2817-5 Hui, 2017, The British Society for Rheumatology guideline for the management of gout, Rheumatology, 56, e1, 10.1093/rheumatology/kex156 Qaseem, 2017, Management of acute and recurrent gout: A clinical practice guideline from the American College of Physicians, Ann Intern Med, 166, 58, 10.7326/M16-0570 Li, 2017, Serum uric acid levels and multiple health outcomes: Umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies, BMJ, 357, j2376, 10.1136/bmj.j2376 Zoppini, 2009, Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients, Diabetes Care, 32, 1716, 10.2337/dc09-0625 Ong, 2010, Serum uric acid doesn’t predict cardiovascular or all cause mortality in type 2 diabetes: The Fremantle Diabetes Study, Diabetologia, 53, 1288, 10.1007/s00125-010-1735-7 Panero, 2012, Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: A population-based study, Atherosclerosis, 221, 183, 10.1016/j.atherosclerosis.2011.11.042 Yuan, 2015, Serum uric acid levels and risk of metabolic syndrome: A dose-response meta-analysis of prospective studies, J Clin Endocrinol Metab, 100, 4198, 10.1210/jc.2015-2527 Feig, 2008, Uric acid and cardiovascular risk, N Engl J Med, 359, 1811, 10.1056/NEJMra0800885 Martinez-Castelao, 2014, Documento de consenso para la detección y manejo de la enfermedad renal crónica, Nefrologia, 34, 243 Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet. 2010;375: 2073-2081. 1985, 727 Fang, 2000, Serum uric acid and cardiovascular mortality, JAMA, 283, 2404, 10.1001/jama.283.18.2404 Culleton, 1999, Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study, Ann Intern Med, 131, 7, 10.7326/0003-4819-131-1-199907060-00003 Palmer, 2013, Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts, BMJ, 347, f4262, 10.1136/bmj.f4262 White, 2016, Plasma urate concentration and risk of coronary heart disease: A Mendelian randomisation analysis, Lancet Diabetes Endocrinol, 4, 327, 10.1016/S2213-8587(15)00386-1 Sluijs, 2015, A Mendelian randomization study of circulating uric acid and type 2 diabetes, Diabetes, 64, 3028, 10.2337/db14-0742 Dai, 2016, Combined association of serum uric acid and metabolic syndrome with chronic kidney disease in hypertensive patients, Kidney Blood Press Res, 41, 413, 10.1159/000443443 Odden, 2014, Uric acid levels, kidney function and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 y 1999-2002, Am J Kidney Dis, 64, 550, 10.1053/j.ajkd.2014.04.024 Chaudhary, 2013, Urid acid: Key ingredient in the recipe for cardio renal metabolic syndrome, Cardiorenal Med, 3, 208, 10.1159/000355405 Subirana, 2011, Specific characteristics of sudden death in Mediterranean area, Am J Cardiol., 107, 622, 10.1016/j.amjcard.2010.10.028 Kojima, 2017, Rationale, design, and baseline characteristics of a study to evaluate the effects of febuxostat in preventing cerebral, cardiovascular and renal events in patients with hyperuricemia, J Cardiol, 69, 169, 10.1016/j.jjcc.2016.02.015